Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News PZ Wind Down Inc PZRXQ

Healthcare Biotechnology
Pz Wind Down, Inc., formerly, PhaseRx, Inc. is a biopharmaceutical company developing a portfolio of mRNA products to correct life-threatening inherited liver diseases in children. The Company's initial product development focus is on urea cycle disorders, a group of rare genetic diseases that generally present before the age of 12 and are characterized by the body's inability to remove ammonia... see more

Recent & Breaking News (GREY:PZRXQ)

PhaseRx to Present at Upcoming Investor Conferences

PR Newswire February 27, 2017

PhaseRx to Present Data for PRX-OTC at the 13th Annual WORLDSymposium™ 2017

PR Newswire February 8, 2017

Research Reports Coverage on Biotech Stocks -- Inovio Pharma, Intra-Cellular Therapies, PhaseRx, and Global Blood Therapeutics

PR Newswire February 7, 2017

PhaseRx to Present at Biotech Showcase 2017

PR Newswire January 4, 2017

Research Reports Coverage on Biotech Stocks -- Idera Pharma, bluebird bio, Corcept Therapeutics, and PhaseRx

PR Newswire December 16, 2016

15 Biggest Mid-Day Losers For Tuesday

Benzinga.com  November 29, 2016

Mid-Afternoon Market Update: Fang Holdings Drops Following Q3 Results; Recro Pharma Shares Surge

Benzinga.com  November 28, 2016

12 Biggest Mid-Day Gainers For Monday

Benzinga.com  November 28, 2016

Mid-Day Market Update: Crude Oil Up Over 2%; PhaseRx Shares Spike Higher

Benzinga.com  November 28, 2016

Mid-Morning Market Update: Markets Open Lower; Edwards Lifesciences To Buy Valtech Cardio

Benzinga.com  November 28, 2016

PhaseRx Receives Orphan Drug Designation from FDA for PRX-OTC for the Treatment of Ornithine Transcarbamylase Deficiency

PR Newswire November 28, 2016

PhaseRx Announces Positive Safety Results from Large Animal Study with Hybrid mRNA Delivery Technology

PR Newswire November 8, 2016

PhaseRx Reports Third Quarter 2016 Financial Results and Provides Corporate Update

PR Newswire November 7, 2016

PhaseRx to Present at 2016 International mRNA Health Conference

PR Newswire October 25, 2016

PhaseRx, Inc. to Present at The MicroCap Conference on October 24-25 in Philadelphia

Accesswire October 11, 2016

PhaseRx to Present Company Overview at Upcoming Investor Conferences

PR Newswire October 11, 2016

PhaseRx Appoints Peggy Phillips to Board of Directors

PR Newswire August 22, 2016

PhaseRx Advances Product Pipeline for Treatment of Rare Genetic Liver Diseases

PR Newswire June 21, 2016

PhaseRx to Present at the 2016 JMP Securities Life Sciences Conference

PR Newswire June 15, 2016